Journal Article Epublish 5 citations
PubMed: 36902022 DOI: 10.3390/ijms24054591
Assessment of sST2 Behaviors to Evaluate Severity/Clinical Impact of Acute Pulmonary Embolism.
Int J Mol Sci 24(5)
Authors: Luigi Petramala, Antonio Concistrè, Francesca Sarlo, Silvia Baroni, Marianna Suppa, Adriana Servello, Francesco Circosta, Gioacchino Galardo, Orietta Gandini, Luca Marino, Giuseppe Cavallaro, Gino Iannucci, Claudio Letizia
Affiliations
- Department of Translational and Precision Medicine, "Sapienza" University of Rome, 00185 Rome, Italy.
- Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, "Sapienza" University of Rome, 00185 Rome, Italy.
- UOC Chimica, Biochimica e Biologia Molecolare Clinica, Fondazione Policlinico Universitario A. Gemelli I.R.C.C.S. 00185 Rome, Italy.
- Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, 00185 Rome, Italy.
- Emergency Medicine Unit, Department of Emergency-Acceptance, Critical Areas and Trauma, Policlinico "Umberto I", 00185 Rome, Italy.
- Department of Molecular Medicine, "Sapienza" University of Rome, 00185 Rome, Italy.
- Department of Mechanical and Aerospace Engineering, "Sapienza" University of Rome, 00185 Rome, Italy.
- Department of Surgery Pietro Valdoni, "Sapienza" University of Rome, 00185 Rome, Italy.
Abstract
Pulmonary embolism (PE) is a potentially life-threatening disorder. Beyond its usefulness in the prognostic stratification of heart failure, sST2 can represent a biomarker with high utility in several acute conditions. Our study was aimed to investigate whether sST2 can be used as a clinical marker of severity and prognostic outcome in acute PE. We enrolled 72 patients with documented PE and 38 healthy subjects; we measured the plasma concentrations of sST2 to evaluate the prognostic and severity performance of different levels of sST2 according to its association with the pulmonary embolism severity index (PESI) score and several parameters of respiratory function. PE patients had significantly higher levels of sST2 compared with healthy subjects (87.74 ± 17.1 vs. 17.1 ± 0.4 ng/mL, < 0.001); we found higher PESI scores and serum lactate values in the group of patients with sST2 > 35 ng/mL compared with patients with sST2 < 35 ng/mL (138.7 ± 14.9 vs. 103.7 ± 15.1 and 2.43 ± 0.69 vs. 1.025 ± 0.05 mmol/L, respectively; < 0.05). Patients with sST2 > 35 ng/mL showed higher radiological severity of PE compared with patients with sST2 < 35 ng/mL. Moreover, sST2 was the strongest parameter with a discriminative capacity for the development of acute respiratory failure and a PESI score >106 with respect to C reactive protein (CRP), creatinine, d-dimer, and serum lactate. We clearly demonstrated that sST2 significantly increased in PE and that its elevation was associated with disease severity. Therefore, sST2 may be used as a clinical marker in the evaluation of PE severity. However, further studies with larger patient populations are required to confirm these findings.
MeSH
Pulmonary Embolism, C-Reactive Protein, Serum